Firebrick Pharma Limited (ASX:FRE)
Australia · Delayed Price · Currency is AUD 0.0650
+0.0020 (3.17%)
Oct 14, 2025, 10:31 AM AEST
Firebrick Pharma Company Description
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.
It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Firebrick Pharma Limited
| Country | Australia |
| Founded | 2012 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Peter Molloy |
Contact Details
Address: 440 Collins Street Melbourne, 3000 Australia | |
| Phone | 61 1300 301 874 |
| Website | firebrickpharma.com |
Stock Details
| Ticker Symbol | FRE |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000197352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Laurence Molloy BSc, FAICD, MBA | Founder, Executive Chairman and Chief Executive Officer |
| Dr. Stephen Francis Goodall MASc, MBA | Founder, Chief Operating Officer and Executive Director |
| Kavi Bekarma B.Sc., C.A. | Chief Financial Officer |
| Dr. Simon Tucker | Chief Scientific Officer |
| Dr. Monique Baldwin | Head of Regulatory Affairs |
| Stephen Buckley | Company Secretary |